Xenetic Biosciences, Inc. (NASDAQ:XBIO) Short Interest Update

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the recipient of a significant growth in short interest during the month of February. As of February 13th, there was short interest totaling 55,692 shares, a growth of 245.0% from the January 29th total of 16,141 shares. Based on an average daily trading volume, of 28,113 shares, the days-to-cover ratio is presently 2.0 days. Currently, 2.6% of the company’s shares are sold short. Currently, 2.6% of the company’s shares are sold short. Based on an average daily trading volume, of 28,113 shares, the days-to-cover ratio is presently 2.0 days.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Wednesday, January 21st. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Reduce”.

Xenetic Biosciences Stock Up 4.5%

Shares of Xenetic Biosciences stock opened at $2.53 on Friday. The business has a 50 day moving average of $2.27 and a 200 day moving average of $2.88. Xenetic Biosciences has a 52 week low of $1.90 and a 52 week high of $13.93. The company has a market cap of $5.79 million, a PE ratio of -1.23 and a beta of 2.29.

Institutional Investors Weigh In On Xenetic Biosciences

An institutional investor recently bought a new position in Xenetic Biosciences stock. DRW Securities LLC purchased a new stake in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund purchased 13,824 shares of the company’s stock, valued at approximately $30,000. DRW Securities LLC owned 0.60% of Xenetic Biosciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 15.12% of the company’s stock.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.